Investigation of genes coding for inflammatory components in Parkinson's disease

Movement Disorders

Volumn 20, Issue 5, 2005, Pages 569-573

  Håkansson, Anna ^a   Westberg, Lars ^a   Nilsson, Staffan ^b   Buervenich, Silvia ^c   Carmine, Andrea ^c   Holmberg, Björn ^a   Sydow, Olof ^c   Olson, Lars ^c   Johnels, Bo ^a   Eriksson, Elias ^a   Nissabrandt, Hans ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Intercellular adhesion molecule 1; Interferon ; Interferon receptor 2; Interleukin 10; Platelet activating factor acetylhydrolase

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADENINE; ALANINE; ARGININE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GLUTAMINE; GLYCINE; GUANINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; LYSINE; TYROSINE; VALINE;

ADULT; AGE; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; INTRON; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGE FACTORS; ALLELES; BRAIN; CHEMOKINE CCL2; DNA PRIMERS; GENOTYPE; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; INTERLEUKIN-10; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTORS, INTERFERON; TUMOR NECROSIS FACTOR-ALPHA;

EID: 20844446985     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20378     Document Type: Article

References (41)

1. Orth M, Tabrizi SJ. Models of Parkinson's disease. Mov Disord 2003;18:729-737.
2. Markopoulou K, Langston JW. Candidate genes and Parkinson's disease: where to next? Neurology 1999;53:1382-1383.
3. Gasser T. Genetics of Parkinson's disease. J Neurol 2001;248:833-840.
4. Zareparsi S, Camicioli R, Sexton G, et al. Age at onset of Parkinson disease and apolipoprotein E genotypes. Am J Med Genet 2002;107:156-161.
5. Wang J, Zhao CY, Si YM, Liu ZL, Chen B, Yu L. ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset. Mov Disord 2002;17:767-771.
6. Mizuta I, Nishimura M, Mizuta E, et al. Relation between the high production related allele of the interferon-gamma (IFN-gamma) gene and age at onset of idiopathic Parkinson's disease in Japan. J Neurol Neurosurg Psychiatry 2001;71:818-819.
7. Li YJ, Scott WK, Hedges DJ, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002;70:985-993.
8. DeStefano AL, Lew MF, Golbe LI, et al. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet 2002;70:1089-1095.
9. Czlonkowska A, Kurkowska-Jastrzebska I, Czlonkowski A, Peter D, Stefano GB. Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Med Sci Monit 2002;8:165-177.
10. Le W, Rowe D, Xie W, Ortiz I, He Y, Appel SH. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 2001;21:8447-8455.
11. Yamada T, McGeer PL, McGeer EG. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol (Berl) 1992;84:100-104.
12. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995;202:17-20.
13. Araujo DM, Lapchak PA. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience 1994;61:745-754.
14. Ciesielska A, Joniec I, Przybylkowski A, et al. Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease. Acta Neurobiol Exp (Wars) 2003;63:117-126.
15. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease. Acta Neurobiol Exp (Wars) 1999;59: 1-8.
16. Mattila KM, Rinne JO, Lehtimaki T, Roytta M, Ahonen JP, Hurme M. Association of an interleukin 1B gene polymorphism (-511) with Parkinson's disease in Finnish patients. J Med Genet 2002; 39:400-402.
17. McGeer PL, Yasojima K, McGeer EG. Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease. Neurosci Lett 2002;326:67-69.
18. Schulte T, Schols L, Muller T, Woitalla D, Berger K, Kruger R. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. Neurosci Lett 2002;326:70-72.
19. Nishimura M, Kuno S, Mizuta I, et al. Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson's disease. Mov Disord 2003;18:953-955.
20. Nishimura M, Mizuta I, Mizuta E, et al. Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease. Neurosci Lett 2001;311:1-4.
21. Daniel S, Lees A. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993;39:165-172.
22. Lopez-Maderuelo D, Amalich F, Serantes R, et al. Interferon-gamma and interleukin-10 gene polymorphisms in pulmonary tuberculosis. Am J Respir Crit Care Med 2003;167:970-975.
23. Myhr KM, Vagnes KS, Maroy TH, Aarseth JH, Nyland HI, Vedeler CA. Interleukin-10 promoter polymorphisms in patients with multiple sclerosis. J Neurol Sci 2002;202:93-97.
24. Bell R, Collier DA, Rice SQ, et al. Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control analysis in schizophrenia. Biochem Biophys Res Commun 1997;241: 630-635.
25. Mattila KM, Hiltunen M, Rinne JO, et al. Absence of association between an intercellular adhesion molecule 1 gene E469K polymorphism and Alzheimer's disease in Finnish patients. Neurosci Lett 2003;337:61-63.
26. Nakashima H, Inoue H, Akahoshi M, et al. The combination of polymorphisms within interferon-gamma receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus. FEBS Lett 1999;453:187-190.
27. Sredni-Kenigsbuch D. TH1/TH2 cytokines in the central nervous system. Int J Neurosci 2002;112:665-703.
28. Soh J, Donnelly RJ, Kotenko S, et al. Identification and sequence of an accessory factor required for activation of the human interferon gamma receptor. Cell 1994;76:793-802.
29. Linda H, Hammarberg H, Piehl F, Khademi M, Olsson T. Expression of MHC class I heavy chain and beta2-microglobulin in rat brainstem motoneurons and nigral dopaminergic neurons. J Neuroimmunol 1999;101:76-86.
30. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 2000;61:863-866.
31. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene. Eur J Immunogenet 1999;26:1-3.
32. Tjoelker LW, Stafforini DM. Platelet-activating factor acetylhydrolases in health and disease. Biochim Biophys Acta 2000;1488: 102-123.
33. Bazan NG. The neuromessenger platelet-activating factor in plasticity and neurodegeneration. Prog Brain Res 1998;118:281-291.
34. Bennett SA, Chen J, Pappas BA, Roberts DC, Tenniswood M. Platelet activating factor receptor expression is associated with neuronal apoptosis in an in vivo model of excitotoxicity. Cell Death Differ 1998;5:867-875.
35. Hubbard AK, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med 2000;28:1379-1386.
36. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999;156:50-61.
37. Strle K, Zhou JH, Shen WH, et al. Interleukin-10 in the brain. Crit Rev Immunol 2001;21:427-449.
38. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
39. Ross OA, Curran MD, Meenagh A, et al. Study of age-association with cytokine gene polymorphisms in an aged Irish population. Mech Ageing Dev 2003;124:199-206.
40. Wang XY, Hurme M, Jylha M, Hervonen A. Lack of association between human longevity and polymorphisms of IL-1 cluster, IL-6, IL-10 and TNF-alpha genes in Finnish nonagenarians. Mech Ageing Dev 2001;123:29-38.
41. Lio D, Scola L, Crivello A, et al. Gender-specific association between -1082 IL-10 promoter polymorphism and longevity. Genes Immun 2002;3:30-33.